Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
lewy body disease/− nicotine
Le lien est enregistré dans le presse-papiers
Page 1 de 17 résultats
Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The aggregation of alpha-synuclein (alphaS) has been implicated as a critical step in the development of Lewy body diseases (LBD) and multiple system atrophy (MSA). Both retrospective and prospective epidemiological studies have consistently demonstrated an inverse association between cigarette
Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Neuronal nicotinic receptors have been implicated in schizophrenia on the basis of the high incidence of tobacco smoking in patients, abnormalities in cytisine and alpha-bungarotoxin (alphaBGT) binding in the hippocampus, and linkage between auditory P50 deficits and the region of chromosome 15
Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Striatal nicotinic acetylcholine receptors with high affinity for nicotinic agonists are involved with the release of a number of neurotransmitters, including dopamine. Previous findings as to whether these receptors are changed in Parkinson's disease and Alzheimer's disease are inconsistent and no
Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
High-affinity nicotine binding, considered to primarily reflect the presence of CNS alpha 4 beta 2 nicotinic receptor subunits, was examined autoradiographically in brain regions most severely affected by Alzheimer and Parkinson types of pathology. In the midbrain, the high density of binding
Nicotinic receptor distribution in the human thalamus: autoradiographical localization of [3H]nicotine and [125I] alpha-bungarotoxin binding.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The thalamus plays a major role in relaying and transforming information that is relayed to the cortex and in turn modulates cortical outputs. The reticular nucleus projects to the other thalamic nuclei, modulating and integrating their activity. The distribution of high affinity nicotine and
Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Human brain ageing is associated with reductions in a variety of nicotinic receptors subtypes, whereas changes in age-related disorders including Alzheimer's disease or Parkinson's disease are more selective. In Alzheimer's disease, in the cortex there is a selective loss of the alpha4 (but not
Clinical neurochemistry: developments in dementia research based on brain bank material.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Brain tissue obtained at autopsy continues to provide unique opportunities in current dementia research. Not only is tissue analysis still essential for diagnosis, but investigation of neurochemical pathology, at a level of resolution beyond current in vivo imaging, continues to provide new insights
Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Lewy bodies (LBs) and Lewy neurites (LNs) in the brain constitute the main histopathological features of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and are comprised of amyloid-like fibrils composed of a small protein ( approximately 14 kDa) named alpha-synuclein (alphaS). As the
The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The primary pathology in Alzheimer's disease (DAT) occurs in the basal forebrain cholinergic system (BFCS), which provides the major cholinergic innervation to the neocortex, hippocampus and amygdala. Consistent with the 'cholinergic hypothesis' of dementia in DAT, the most effective treatments so
Nicotinic receptors in human brain: topography and pathology.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Brain nicotinic acetylcholine receptors (nAChR) are a class of ligand-gated channels composed of alpha and beta subunits with specific structural, functional and pharmacological properties. They participate in the physiological and behavioural effects of acetylcholine and mediate responses to
Nicotinic receptor subtypes in human brain related to aging and dementia.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Neuronal nicotinic receptors are attracting increasing interest, beyond their role in relation to tobacco use, in the areas of human brain aging and disorders associated with dementia. Of the different receptor subtypes in the mammalian brain, many decline with normal aging in several different
Treatment of dementia with neurotransmission modulation.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The prevalence of dementia is growing in developed countries where elderly patients are increasing in numbers. Neurotransmission modulation is one approach to the treatment of dementia. Cholinergic precursors, anticholinesterases, nicotine receptor agonists and muscarinic M(2) receptor antagonists
Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Dopaminergic synaptic function may be assessed either at the presynaptic terminal or at the postsynaptic binding sites using molecular in vivo imaging methods. Apart from the density of binding sites, parameters such as alterations in dopamine synthesis, dopamine storage or dopamine release can be
An overview of PET neuroimaging.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Over the past 35 years or so, PET brain imaging has allowed powerful and unique insights into brain function under normal conditions and in disease states. Initially, as PET instrumentation continued to develop, studies were focused on brain perfusion and glucose metabolism. This permitted
Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Nicotinic cholinergic agonists represent a relatively newly developing area for therapeutic intervention in Alzheimer disease (AD) and related neurodegenerative dementias. Loss of cholinergic receptors has been reported not only in AD but also in Parkinson's disease, Lewy body dementia, and
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
